All
Outcomes
Market
Price
AI Fair
Value
Value
Edge
Darryn Peterson
YesNo
AJ Dybantsa
YesNo
Cameron Boozer
YesNo
Caleb Wilson
YesNo
Tounde Yessoufou
YesNo
Jayden Quaintance
YesNo
Mikel Brown Jr.
YesNo
Koa Peat
YesNo
Nate Ament
YesNo
AI Insights:
03.16 14:35 UpdatedFair Value Reasoning:
AJ Dybantsa's stock has surged following his historic Big 12 tournament run (breaking Kevin Durant's scoring record) and subsequent reports from Jeff Goodman that NBA executives 'overwhelmingly' prefer him over Peterson. Conversely, Darryn Peterson is facing significant headwinds: a poor tournament showing (8-for-28 shooting) and the alarming revelation of 'traumatic' full-body cramping issues persisting since September, raising major medical red flags. The current market split of 55.5c/36c does not fully price in these new medical concerns; Dybantsa's lead should be significantly wider.
Sign up to view more information
Divergence
Significant divergence exists. Recent reports from mainstream media and insiders (e.g., Jeff Goodman) indicate that NBA executives now 'overwhelmingly' prefer AJ Dybantsa, suggesting the race is not even close due to Peterson's medical flags and recent poor play. However, the prediction market still assigns Peterson a 36% implied probability, which is significantly high relative to the latest scouting consensus, indicating a lag in pricing in the negative medical news.
